Merck has received a significant endorsement from the EU’s CHMP for a subcutaneous formulation of KEYTRUDA®, enhancing its delivery method for patients. This advancement not only broadens treatment options but also underscores Merck’s commitment to innovation in cancer care.
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed in
Source: Original Press Release
